MedTrace Logo

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

NCT00050076 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2012-02-02

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

MCC-135

MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks

DRUG

MCC-135

MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks

DRUG

MCC-135

MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks

DRUG

Placebo

MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks

Sponsors & Collaborators

Principal Investigators

  • VP Clinical Science Strategy · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2003-08-31
Completion
2003-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050076 on ClinicalTrials.gov